Condition category
Circulatory System
Date applied
Date assigned
Last edited
Prospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
When people suffer from chest pain we are often worried that the pains may be coming from a heart problem such as a heart attack. It is often difficult to tell quickly if a patient has pain from a heart problem or from something less serious like a muscle strain. Unfortunately, current blood tests do not give accurate results until at least 12 hours after the chest pain started. This often means an anxious wait and a delay before treatment can start. To help with the problem, we have developed the ‘Manchester Acute Coronary Syndromes (MACS) decision rule’ from research involving over 1,200 patients. This rule uses blood test results and clinical information collected by the doctor. This rule could identify quickly who has had a heart attack. Many people could be safely reassured that they have not had a heart attack and could go home, avoiding unnecessary hospital admission for further tests. The MACS decision rule also helps doctors to make accurate decisions about the most appropriate ward for patients who do need admission. Before using the rule in practice, we must determine whether using it in reality produces measurable benefit. This will require a large study at many centres across the country. Before starting on this, we aim to run a smaller study that will find out the possibility of conducting such a large study.

Who can participate?
Adult patients who come to the Emergency Department with chest pain that doctors suspect may have been caused by a heart attack.

What does the study involve?
Participants will be randomly allocated to either the usual care group or the MACS decision rule group. Those in the usual care group will receive the usual care, with no changes. Where permission is granted, we will take additional blood samples from these participants when they arrive at the Emergency Department and 1 hour later. The samples will be stored to be tested for markers of heart disease at a later date. This will help us to improve the quality of our tests for heart disease.
Participants who are allocated to the MACS decision rule group will have their care guided by the MACS decision rule. The initial tests may identify that it is safe for these participants to return home without hospital admission. If so, participants and doctors can still jointly decide whether this is the most appropriate course of action for the individual participant. The MACS decision rule will also allocate participants to one of four risk groups, which the doctor can use to decide the best area of the hospital for the participant to be treated in. Participants who are discharged from hospital early because of the decision rule will be given a follow up appointment. This will usually take place on the following day, but can also be arranged for any time within the next 3 days. This will allow staff to take an extra blood sample as an extra check that the participant’s heart has not suffered any damage. We also want to find out about participants’ experiences of taking part in this research. We will invite some participants to give us a detailed account of their experiences, either during a telephone interview or during a focus group interview with between 4 and 8 other participants. We will record the interviews to make sure that we do not miss important details. It is very important that we know whether the people taking part in this research experience any further medical problems soon after discharge. We will therefore contact participants, by telephone, email, letter or even a home visit (whichever is most convenient) after 7 days, 30 days and 6 months. Finally, we will send participants a questionnaire through the post after 30 days, 3 months and 6 months to find out the details of any health problems you may have had and to work out the costs of those problems to the National Health Service (NHS).

What are the possible benefits and risks of participating?
We cannot promise that taking part in this study will bring benefits to individual participants. It is possible that they will be able to return home sooner. If participants are invited and agree to take part in a focus group or a telephone interview to explore their experiences, we will offer them a £10 high street voucher as a token of our thanks and, if they have to travel to the hospital for this, we will reimburse travel and parking expenses. As the project does not involve changing the drugs that participants are taking, the risks of taking part are minimal. Our previous research suggests that the risks of patients being discharged with an undetected heart attack are extremely small. If participants do go home earlier than usual, we will give them an early appointment for a further blood test. If they did have a heart attack that had not previously been detected, it will be picked up by this blood test. If a heart attack is detected, participants will still receive all the appropriate treatment. In very rare cases, taking blood can lead to prolonged bleeding, bruising, accidental damage to the blood vessels and/or infections. However, all blood samples will be drawn by experienced staff members who have received appropriate training. The small amount of blood taken will not have any harmful effects for the participant’s body.

Where is the study run from?
The study is sponsored by Central Manchester University Hospitals NHS Foundation Trust, UK and will take place at Manchester Royal Infirmary and Salford Royal Hospital, UK.

When is study starting and how long is it expected to run for?
We estimate that the study will commence in August 2013 and is expected to last for between 4 and 6 months.

Who is funding the study?
The National Institute for Health Research (NIHR), UK is funding this study.

Who is the main contact?
Dr. Richard Body

Trial website

Contact information



Primary contact

Dr Richard Body


Contact details

Manchester Royal Infirmary
Oxford Road
M13 9WL
United Kingdom
+44 161 276 8539

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Reducing unnecessary admissions for chest pain with the Manchester Acute Coronary Syndromes (MACS) decision rule: feasibility study



Study hypothesis

The aim of this study is to evaluate the feasibility of a multicentre randomised controlled trial to evaluate whether use of the MACS clinical decision rule can safely reduce unnecessary hospital admissions for suspected cardiac chest pain.

Ethics approval

21/03/2013, ref: 13/NW/0081

Study design

Randomised; Interventional; Design type: Diagnosis, Not specified

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Topic: Cardiovascular, Injuries and Emergencies; Subtopic: Cardiovascular (all Subtopics), Injuries and Emergencies (all Subtopics); Disease: Injuries and Emergencies, Congenital Heart Disease and Pulmonary Hypertension


1. Control Group: Care of the control group will be guided by local Emergency Department guidelines for the management of suspected cardiac chest pain, which are compliant with current national and international guidance.
2. The intervention group: MACS Decision Rule. This group will have their care in the Emergency Department guided by the use of the Manchester Acute Coronary Syndromes (MACS) clinical decision rule, which combines clinical features with levels of two cardiac biomarkers.
Follow Up Length: 6 month(s); Study Entry : Single Randomisation only

Intervention type



Not Applicable

Drug names

Primary outcome measures

Successful early discharge, defined as a decision to discharge from the ED within 4 hours of arrival; Timepoint(s): Assessed once (can be assessed from 30 days after randomisation) (Primary clinical outcome).

Secondary outcome measures

1. Acceptability of trial processes to clinicians and patients; Timepoint(s): Within 30 days of randomisation (feasibility outcome)
2. Attrition (including both failure to complete the trial protocol and loss to follow up); Timepoint(s): Assessed once, on study completion (feasibility outcome)
3. Completeness of data collection; Timepoint(s): Assessed once, on study completion (feasibility outcome)
4. Direct healthcare costs; Timepoint(s): 30 days, 3 months, 6 months
5. Health status (EQ-5D); Timepoint(s): 30 days, 3 months, 6 months
6. Length of initial hospital stay; Timepoint(s): Assessed once, on study completion (clinical outcome)
7. Major adverse cardiac events (death, coronary revascularisation, acute myocardial infarction); Timepoint(s): 30 days, 3 months, 6 months
8. Patient satisfaction; Timepoint(s): 30 days and 6 months
9. Reasons for lack of compliance with the trial protocol; Timepoint(s): Within 30 days of randomisation (feasibility outcome)
10. The number of eligible patients; Timepoint(s): Assessed once, upon study completion (feasibility outcome)
11. The proportion of eligible patients randomised; Timepoint(s): Assessed once, on study completion (feasibility outcome)

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

Consenting patients, over 18 years of age, presenting to the ED with pain, discomfort or pressure in the chest, epigastrium, neck, jaw, or upper limb without an apparent non-cardiac source (compatible with the American Heart Association case definitions), which the treating physician believes warrants investigation for a possible acute coronary syndrome.; Target Gender: Male & Female; Upper Age Limit 150 years ; Lower Age Limit 18 years

Participant type


Age group




Target number of participants

Planned Sample Size: 100; UK Sample Size: 100

Participant exclusion criteria

1. Peak symptoms occurred more than 24 hours prior to presentation
2. Another medical condition necessitating hospital admission
3. Definite ST elevation myocardial infarction needing immediate revasularisation
4. No capacity to provide informed consent
5. Inability to communicate in English language if translation services are unavailable
6. Prisoners

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Manchester Royal Infirmary
M13 9WL
United Kingdom

Sponsor information


Central Manchester University Hospitals NHS Trust (CMFT) (UK)

Sponsor details

Emergency Department
Manchester Royal Infirmary
Oxford Road
M13 9WL
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

National Institute for Health Research

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

Federal/National Government


United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes

18/07/2016: No publications found, verifying study status with principal investigator.